<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02615639</url>
  </required_header>
  <id_info>
    <org_study_id>SunYatSenIDD</org_study_id>
    <nct_id>NCT02615639</nct_id>
  </id_info>
  <brief_title>A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in CHB</brief_title>
  <acronym>CTHBVACADCHB</acronym>
  <official_title>A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The anti-virus effects is not satisfying in some of Chronic Hepatitis B（CHB) patients who
      have been on anti-Hepatitis B Virus (HBV) drugs therapy. Dendritic cell (DC) is critical in
      Hepatitis B Virus (HBV) specific immunity in the process of producing HBV promoter specific
      cytotoxic T cells (CTLs) and specific T helper cells (HTLs), however they are defective in
      CHB patients. Therefore, if it were going to remove HBV completely, it mainly depends if the
      body itself can produce enough HBV specific cytotoxic T cells (CTLs) and specific T helper
      cells (HTLs). Our research is to plus Hepatitis B Vaccine Activated-DCs therapy to CHB
      patients who have been on anti-HBV drugs but with poor effects, supposing to significantly
      improve anti-HBV efficacy, even to clean HBV from the patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who have been on anti-HBV therapy Complying with the inclusion criteria will be
      enrolled into our research, Nucleoside analogues (NAs,entecavir） treatment for more than 1
      year or interferon（IFN)-a-2a (IFN-a-2a,Pegasys） treatment for more than 24 weeks. The
      patients will be randomly assigned to experimental group and control group with the ratio of
      2:1, one group (control group) will go on receive the anti-HBV drugs treatment solely;
      another group (experimental group) after enrollment will immediately receive the Hepatitis B
      Vaccine activated-DCs (HPDC-T cells) for 24 weeks (every 2 weeks once for 24 weeks, 12 times
      in total), at the same time co-use anti-HBV drugs treatment, as for Pegasys, it will go on to
      be used for 12 weeks after HPDC-T cells treatment completed.

      The technical route of HBV-T cells prepared: First, investigators collect fresh blood of CHB,
      mononuclear cells were isolated, and induced to HBsAg pulsed DCs in Hepatitis B vaccine
      (Shenzhen kangtai, Shenzhen, China) and interleukin-4（IL-4)/granulocyte-macrophage
      colony-stimulating factor(GM-CSF） (Perprotech, New Jersey, USA) (7 days), then co-culture of
      DCs and Peripheral Blood Mononuclear Cell(PBMCs ）7days, obtain HBV specific T cells, return
      to the patient finally.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatitis B surface Antigen （HBeAg）seroconversion</measure>
    <time_frame>3 years</time_frame>
    <description>to increase Hepatitis B surface antigen (HBsAg) loss rate from 1% up to 11% or more</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by low-grade fever, Infection and shock.</measure>
    <time_frame>one and a half year</time_frame>
    <description>Safety profiles include side effects of anti-HBV drugs(ETV,LDT and IFN-a), viral resistance of anti-HBV drugs. And side effects of HPDC-T cells infusion,such as low-grade fever, Infection and shock.The difference of side effects rates between anti-HBV drugs monotherapy and anti-HBV drugs plus HPDC-T cells combined therapy will also be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatitis B envelope Antigen （HBeAg） seroconversion</measure>
    <time_frame>3 years</time_frame>
    <description>to increase HBeAg negative rate by 12 percentage points on the basis of the existing data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV DNA clearance</measure>
    <time_frame>3 years</time_frame>
    <description>to increase the undetectable rate of HBV DNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT recovery</measure>
    <time_frame>3 years</time_frame>
    <description>to increase the recovery rate of ALT</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>HPDC-T cells &amp; entecavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPDC-T cells 1-5×10^5 intravenous injection, every 2 weeks for 24 weeks , and entecavir(ETV) 0.5mg tablet by mouth, every night.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>entecavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>entecavir 0.5mg tablet by mouth, every night.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HPDC-T cells &amp; IFN-a-2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPDC-T cells 1-5×10^5 intravenous injection, every 2 weeks for 24 weeks ,and IFN-a-2a 180ug subcutaneous injection， every week for 9 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IFN-a-2a</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IFN-a-2a 180ug subcutaneous injection， every week for 9 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HPDC-T cells &amp; Telbivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPDC-T cells 1-5×10^5 intravenous injection, every 2 weeks for 24 weeks ,and Telbivudine 600mg tablet by mouth, every night.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telbivudine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telbivudine 600mg tablet by mouth, every night.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HPDC-T cells &amp; Entecavir</intervention_name>
    <description>experimental groups will be given HPDC-T cells &amp; Entecavir. HPDC-T cells will be given for 24weeks on the basis of anti-HBV therapy ,and entecavir 0.5mg tablet every night by mouth</description>
    <arm_group_label>HPDC-T cells &amp; entecavir</arm_group_label>
    <other_name>Hepatitis B Vaccine Activated-DCs &amp; Entecavir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>0.5mg tablet every night by mouth</description>
    <arm_group_label>entecavir</arm_group_label>
    <other_name>Baraclude</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HPDC-T cells &amp; IFN-a-2a</intervention_name>
    <description>experimental groups will be given HPDC-T cells &amp; IFN-a-2a. HPDC-T cells will be given for 24 weeks on the basis of anti-HBV therapy ,and IFN-a-2a 180ug subcutaneous injection every week</description>
    <arm_group_label>HPDC-T cells &amp; IFN-a-2a</arm_group_label>
    <other_name>Hepatitis B Vaccine Activated-DCs &amp; Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IFN-a-2a</intervention_name>
    <description>IFN-a-2a 180ug subcutaneous injection every week</description>
    <arm_group_label>IFN-a-2a</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HPDC-T cells &amp; Telbivudine</intervention_name>
    <description>experimental groups will be given HPDC-T cells &amp; Telbivudine. HPDC-T cells will be given for 24weeks on the basis of anti-HBV therapy ,and Telbivudine 600mg tablet every day by mouth</description>
    <arm_group_label>HPDC-T cells &amp; Telbivudine</arm_group_label>
    <other_name>Hepatitis B Vaccine Activated-DCs &amp; Telbivudine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telbivudine</intervention_name>
    <description>Telbivudine 600mg tablet every day by mouth</description>
    <arm_group_label>Telbivudine</arm_group_label>
    <other_name>LDT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic hepatitis B patients, aged 18~65，Chinese

          -  have been on entecavir（ETV） or telbivudine（LDT） treatment for more than 1 year,and HBV
             DNA&lt;100 IU/ml（Roche Cobas）;or have been on

          -  have been on PEG-IFN treatment for more than 24 weeks,and 20 &lt; HBV DNA &lt; 20000
             IU/ml（Roche Cobas）.

          -  HBsAg 100~5000 IU/ml

          -  HBeAg 10~500 COI

        Exclusion Criteria:

          -  Superinfection or co-infection with hepatitis A, C, D, E, cytomegalovirus and HIV, or
             Epstein-Barr virus;

          -  other liver diseases such as alcoholic liver disease, drug-induced hepatitis, Wilson
             disease and autoimmune hepatitis;

          -  ascites or gastrointestinal bleeding or peptic ulcer or esophageal varix by electronic
             gastroscope examination;

          -  liver cirrhosis (including compensated and decompensated cirrhosis) and liver failure;

          -  severe bacterial or fungal infections;

          -  a history of diabetes or cardiac disease or hypertension or nephrosis;

          -  pregnant women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lubiao Chen, MD.&amp;PHD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Third Affiliated Hospital of Sun Yet-sun University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yurong Gu, MD.</last_name>
    <phone>18588628204</phone>
    <phone_ext>+86</phone_ext>
    <email>guyr163@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuehua Huang, MD.&amp;PHD.</last_name>
    <phone>18922103516</phone>
    <phone_ext>+86</phone_ext>
    <email>huangyh53@mail.sysu.edu.cn</email>
  </overall_contact_backup>
  <reference>
    <citation>Luo J, Li J, Chen RL, Nie L, Huang J, Liu ZW, Luo L, Yan XJ. Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers. Vaccine. 2010 Mar 16;28(13):2497-504. doi: 10.1016/j.vaccine.2010.01.038. Epub 2010 Jan 29.</citation>
    <PMID>20117267</PMID>
  </reference>
  <reference>
    <citation>Akbar SM, Furukawa S, Horiike N, Abe M, Hiasa Y, Onji M. Safety and immunogenicity of hepatitis B surface antigen-pulsed dendritic cells in patients with chronic hepatitis B. J Viral Hepat. 2011 Jun;18(6):408-14. doi: 10.1111/j.1365-2893.2010.01320.x.</citation>
    <PMID>20487261</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2015</study_first_submitted>
  <study_first_submitted_qc>November 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2015</study_first_posted>
  <last_update_submitted>November 24, 2015</last_update_submitted>
  <last_update_submitted_qc>November 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Yuehua Huang</investigator_full_name>
    <investigator_title>chief director of liver Lab</investigator_title>
  </responsible_party>
  <keyword>HPDC-T cells</keyword>
  <keyword>CHB</keyword>
  <keyword>immuno therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Telbivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

